Femasys Inc. (NASDAQ:FEMY) Stock Short Interest Report for October

Femasys Inc. (NASDAQ:FEMY) saw a large decline in short interest in the month of October. As of October 15th, there was short interest totaling 164,106 shares, a decline of 71.6% from the September 30th total of 577,249 shares. Based on an average trading volume of 108,262 shares, the days-to-cover ratio is presently 1.5 days. Approximately 2.1% of the company’s shares are sold short.

Femasys Trading Up 1.9%

Shares of NASDAQ:FEMY traded up $0.03 on Wednesday, reaching $1.40. The company had a trading volume of 8,166 shares, compared to its average volume of 260,479. Femasys has a 52-week low of $1.32 and a 52-week high of $22.20. The firm’s 50 day simple moving average is $2.36 and its 200-day simple moving average is $6.34. The firm has a market capitalization of $11.69 million, a PE ratio of -0.40 and a beta of -2.16.

Femasys (NASDAQ:FEMY) last issued its quarterly earnings data on Friday, August 14th. The company reported ($1.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.31) by ($0.02). The company had revenue of $0.33 million during the quarter, compared to analysts’ expectations of $0.73 million.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Wall Street Zen upgraded Femasys from a “strong sell” rating to a “sell” rating in a report on Saturday, October 17th. Weiss Ratings downgraded Femasys from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, August 17th. Lake Street Capital lowered their price objective on shares of Femasys to $10.00 and set a “buy” rating for the company in a research note on Tuesday, August 18th. Finally, Maxim Group cut their target price on shares of Femasys to $10.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Femasys currently has an average rating of “Moderate Buy” and a consensus target price of $50.00.

Insider Buying and Selling at Femasys

In other Femasys news, CEO Kathy Lee-Sepsick bought 15,625 shares of Femasys stock in a transaction on Friday, August 7th. The shares were acquired at an average price of $3.20 per share, for a total transaction of $50,000.00. Following the completion of the purchase, the chief executive officer directly owned 15,625 shares in the company, valued at approximately $50,000. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Dov Elefant bought 15,625 shares of the firm’s stock in a transaction dated Friday, August 7th. The shares were acquired at an average price of $3.20 per share, with a total value of $50,000.00. Following the completion of the transaction, the chief financial officer owned 15,625 shares of the company’s stock, valued at approximately $50,000. The trade was a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders acquired a total of 38,750 shares of company stock worth $124,000 in the last ninety days. 7.75% of the stock is currently owned by corporate insiders.

Femasys Company Profile

Femasys Inc is a biotechnology and medical device company focused on developing and commercializing products for women’s health. The company’s portfolio is centered on solutions for permanent birth control, fertility evaluation and treatment, and related gynecological procedures.

Femasys’ products include FemVue, a device used with saline and air to assess fallopian tube patency during fertility evaluations. The company is also developing FemBloc, a non-surgical, investigational permanent birth control system designed for placement through the fallopian tubes.